Rivaroxaban, a factor Xa inhibitor, improves neovascularization in the ischemic hindlimb of streptozotocin-induced diabetic mice
作者： Tao-Cheng Wu , Jenq-Shyong Chan , Chiu-Yang Lee , Hsin-Bang Leu , Po-Hsun Huang
DOI: 10.1186/S12933-015-0243-Y
关键词: Neovascularization 、 Cell aging 、 Angiogenesis 、 Factor Xa Inhibitor 、 Vascular endothelial growth factor 、 Endocrinology 、 Medicine 、 Endothelial progenitor cell 、 Vascular endothelial growth factor A 、 Internal medicine 、 Rivaroxaban 、 Endocrinology, Diabetes and Metabolism 、 Cardiology and Cardiovascular Medicine
摘要: Factor Xa inhibitor is used for preventing venous thromboembolism (VTE) in adult patients receiving orthopedic operation. However, the role of factor inhibitor, rivaroxaban, angiogenesis still unknown. Streptozotocin (STZ)–induced diabetic mice with model hind-limb ischemia, were divided into non-diabetic control, and low- high-dose rivaroxaban treatment groups, order to evaluate effect angiogenesis. Doppler perfusion imaging showed that blood flow recovery was significantly increased, more capillary density occurred group. In vitro studies, human endothelial progenitor cells (EPCs) treated had significant functional improvement migration senescence under hyperglycemic conditions. Rivaroxaban also increased nitric oxide synthase (eNOS) as well vascular growth (VEGF) expressions hyperglycemia-stimulated EPCs. promoted vessel formation improved cell function These effects may be associated enhancement expression eNOS VEGF.
biomedcentral.com
springer.com
core.ac.uk
paperity.org参考文章(34)
Soledad Lange, Ibeth Gonzalez, Mauricio P Pinto, Maximiliano Arce, Rodrigo Valenzuela, Evelyn Aranda, Matias Elliot, Marjorie Alvarez, Soledad Henriquez, Ethel V Velasquez, Felipe Orge, Barbara Oliva, Pamela Gonzalez, Manuel Villalon, Kelly M Cautivo, Alexis M Kalergis, Karla Pereira, Camila Mendoza, Claudia Saez, Sumie Kato, Mauricio A Cuello, Fernanda Parborell, Griselda Irusta, Veronica Palma, Miguel L Allende, Gareth I Owen, None, Independent anti-angiogenic capacities of coagulation factors X and Xa. Journal of Cellular Physiology. ,vol. 229, pp. 1673- 1680 ,(2014) , 10.1002/JCP.24612
Henk. M. W. Verheul, Herbert M. Pinedo, Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition Nature Reviews Cancer. ,vol. 7, pp. 475- 485 ,(2007) , 10.1038/NRC2152
Greg L. Plosker, Rivaroxaban: a review of its use in acute coronary syndromes. Drugs. ,vol. 74, pp. 451- 464 ,(2014) , 10.1007/S40265-014-0188-6
Jinglian Yan, Guodong Tie, Brian Park, Yagai Yan, Philip T. Nowicki, Louis M. Messina, Recovery from hind limb ischemia is less effective in type 2 than in type 1 diabetic mice: roles of endothelial nitric oxide synthase and endothelial progenitor cells. Journal of Vascular Surgery. ,vol. 50, pp. 1412- 1422 ,(2009) , 10.1016/J.JVS.2009.08.007
J Herbert, F Bono, J Herault, C Avril, F Dol, A Mares, P Schaeffer, Effector protease receptor 1 mediates the mitogenic activity of factor Xa for vascular smooth muscle cells in vitro and in vivo. Journal of Clinical Investigation. ,vol. 101, pp. 993- 1000 ,(1998) , 10.1172/JCI1833
Lars C. Borris, Rivaroxaban and dabigatran etexilate: two new oral anticoagulants for extended postoperative prevention of venous thromboembolism after elective total hip arthroplasty Archives of Orthopaedic and Trauma Surgery. ,vol. 130, pp. 583- 589 ,(2010) , 10.1007/S00402-009-0930-9
Qianxing Zhou, Florian Bea, Michael Preusch, Hongjie Wang, Berend Isermann, Khurrum Shahzad, Hugo A. Katus, Erwin Blessing, Evaluation of plaque stability of advanced atherosclerotic lesions in apo E-deficient mice after treatment with the oral factor Xa inhibitor rivaroxaban. Mediators of Inflammation. ,vol. 2011, pp. 432080- 432080 ,(2011) , 10.1155/2011/432080
Michael A. Kuliszewski, Michael R. Ward, James W. Kowalewski, Alexandra H. Smith, Duncan J. Stewart, Michael J. Kutryk, Howard Leong-Poi, A direct comparison of endothelial progenitor cell dysfunction in rat metabolic syndrome and diabetes Atherosclerosis. ,vol. 226, pp. 58- 66 ,(2013) , 10.1016/J.ATHEROSCLEROSIS.2012.09.029
Po-Hsun Huang, Shao-Sung Huang, Yung-Hsiang Chen, Chih-Pei Lin, Kuang-Hsing Chiang, Jia-Shiong Chen, Hsiao-Ya Tsai, Feng-Yen Lin, Jaw-Wen Chen, Shing-Jong Lin, Increased circulating CD31+/annexin V+ apoptotic microparticles and decreased circulating endothelial progenitor cell levels in hypertensive patients with microalbuminuria. Journal of Hypertension. ,vol. 28, pp. 1655- 1665 ,(2010) , 10.1097/HJH.0B013E32833A4D0A
Cyrus V. Desouza, Does drug therapy reverse endothelial progenitor cell dysfunction in diabetes Journal of Diabetes and Its Complications. ,vol. 27, pp. 519- 525 ,(2013) , 10.1016/J.JDIACOMP.2013.04.007